Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG02 +/- Pembrolizumab in RAS Mutant Colorectal Cancer
NCT02933944Phase 1Terminated
- Sponsor
- Targovax
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of TG02 in colorectal cancer (CRC) (2 arms), sponsored by Targovax. Primary endpoints: Patients Safety During Study up to 20 weeks, Patients' Immune Response Assessed by Delayed Type Hypersensitive (DTH) Test at 8 weeks and 2 more. Started Sep 2016; status: terminated.
02
Drugs
TG02
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02933944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933944.